Betta Pharmaceuticals Co Ltd Total Assets
Betta Pharmaceuticals Co Ltd total assets. Based on the latest financial reports, Betta Pharmaceuticals Co Ltd (300558) holds total assets worth CN¥10.69 Billion CNY (≈ $1.56 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300558 cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Betta Pharmaceuticals Co Ltd (2011–2025)
Total assets of Betta Pharmaceuticals Co Ltd from 2011 to 2025. This chart illustrates how Betta Pharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data. See 300558 live share price for real-time trading data and today's change.
Betta Pharmaceuticals Co Ltd - Asset Composition Analysis
Betta Pharmaceuticals Co Ltd Total Assets Breakdown (December 2025)
Betta Pharmaceuticals Co Ltd total assets breakdown as of December 2025. Betta Pharmaceuticals Co Ltd's total assets of CN¥10.69 Billion consist of 14.9% current assets and 85.1% non-current assets. Explore 300558 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.1% |
| Accounts Receivable | CN¥351.26 Million | 3.3% |
| Inventory | CN¥381.16 Million | 3.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.82 Billion | 26.7% |
| Goodwill | CN¥413.58 Million | 3.9% |
Asset Composition Trend (2011–2025)
This chart illustrates how Betta Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Betta Pharmaceuticals Co Ltd's current assets represent 14.9% of total assets in 2025, a decrease from 18.7% in 2011.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 9.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, a decrease from 42.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 26.7% of total assets.
Betta Pharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Betta Pharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Abbott India Limited
NSE:ABBOTINDIA
|
India | Rs56.94 Billion |
|
Shenzhen Salubris Pharmaceuticals Co Ltd
SHE:002294
|
China | CN¥10.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥4.51 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
Betta Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.99 | 0.62 | 3.21 |
| Quick Ratio | 0.78 | 0.48 | 2.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-15.94 Million | CN¥-790.69 Million | CN¥1.27 Billion |
Betta Pharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Betta Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.27 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 13.1% |
| Total Assets | CN¥10.57 Billion |
| Market Capitalization | $2.62 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Betta Pharmaceuticals Co Ltd's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Betta Pharmaceuticals Co Ltd's assets grew by 13.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Betta Pharmaceuticals Co Ltd (2011–2025)
The table below shows the annual total assets of Betta Pharmaceuticals Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥10.57 Billion ≈ $1.55 Billion |
+13.10% |
| 2024-12-31 | CN¥9.34 Billion ≈ $1.37 Billion |
+2.13% |
| 2023-12-31 | CN¥9.15 Billion ≈ $1.34 Billion |
+15.64% |
| 2022-12-31 | CN¥7.91 Billion ≈ $1.16 Billion |
+26.13% |
| 2021-12-31 | CN¥6.27 Billion ≈ $917.71 Million |
+19.67% |
| 2020-12-31 | CN¥5.24 Billion ≈ $766.87 Million |
+26.79% |
| 2019-12-31 | CN¥4.13 Billion ≈ $604.84 Million |
+17.76% |
| 2018-12-31 | CN¥3.51 Billion ≈ $513.63 Million |
+26.58% |
| 2017-12-31 | CN¥2.77 Billion ≈ $405.78 Million |
+27.95% |
| 2016-12-31 | CN¥2.17 Billion ≈ $317.14 Million |
+88.95% |
| 2015-12-31 | CN¥1.15 Billion ≈ $167.85 Million |
+73.03% |
| 2014-12-31 | CN¥662.93 Million ≈ $97.01 Million |
+61.37% |
| 2013-12-31 | CN¥410.81 Million ≈ $60.11 Million |
+57.40% |
| 2012-12-31 | CN¥261.00 Million ≈ $38.19 Million |
+21.33% |
| 2011-12-31 | CN¥215.11 Million ≈ $31.48 Million |
-- |
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more